Business News, In Brief
Executive Summary
Pfizer Lays Out Primary Care Business Development Opportunities
You may also be interested in...
As More Indian Companies Dive Into Biosimilars, Will Success In Generic Drugs Repeat?
MUMBAI - In August, when leading Indian drug maker Dr. Reddy's Labs launched Cresp, a biosimilar brand of Amgen's darbepoetin alfa Aranesp, G.V.Prasad, Reddy's chief executive officer exulted at a media briefing that his company may well be on course to becoming the largest biologics player in the world in a few years, next only to Swiss giant Roche
Merck And Teva Settle Temodar Patent Suit, But Appeals Case Continues
Teva will launch its generic only if an appeals court finds the Temodar patent is unenforceable; otherwise it can do so six months before the patent expires.
Merck Pumps Pipeline With $800M Cardiome Deal
FDA-delayed vernakalant for atrial fibrillation nets handsome pact, as more-lucrative oral form awaits Phase III trials.